1.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

2.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

3.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

4.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

5.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

6.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

7.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

8.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

9.

Conference Highlights of the 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses,4-8 June 2011, Leuven, Gembloux, Belgium.

1.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

2.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

3.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

4.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

5.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

6.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

7.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

8.

Organ Procurement and Transplantation in Belgium. ; Prélèvement et transplantation d'organes en Belgique

1.

Prévalence de la maladie rénale au stade 3 selon l’équation MDRD : comparaison critique des données liégeoises (Belgique) et américaines (étude NHANES)

2.

Prévalence de la maladie rénale au stade 3 selon l’équation MDRD : comparaison critique des données liégeoises (Belgique) et américaines (étude NHANES)

3.

Prévalence de la maladie rénale au stade 3 selon l’équation MDRD : comparaison critique des données liégeoises (Belgique) et américaines (étude NHANES)

1.

Update of the Belgian Association for the Study of the Liver Guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

2.

Update of the Belgian Association for the Study of the Liver Guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

3.

Update of the Belgian Association for the Study of the Liver Guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

4.

Update of the Belgian Association for the Study of the Liver Guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

5.

Update of the Belgian Association for the Study of the Liver Guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

6.

Update of the Belgian Association for the Study of the Liver Guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.

1.

Overweight and obesity : a major problem among belgian adolescents issued from a high risk population.

2.

Overweight and obesity : a major problem among belgian adolescents issued from a high risk population.

3.

Overweight and obesity : a major problem among belgian adolescents issued from a high risk population.

4.

Overweight and obesity : a major problem among belgian adolescents issued from a high risk population.

5.

Overweight and obesity : a major problem among belgian adolescents issued from a high risk population.

6.

Overweight and obesity : a major problem among belgian adolescents issued from a high risk population.

1.

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.

2.

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.

3.

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.

4.

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.

5.

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.

6.

Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience.

1.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis...

2.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis...

3.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis...

4.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis...

5.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis...

6.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis...

1.

Multicenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.

2.

Multicenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.

3.

Multicenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.

4.

Multicenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.

5.

Multicenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.

6.

Multicenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.

1.

Multicenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.

2.

Multicenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.

3.

Multicenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.

4.

Multicenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.

5.

Multicenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.

6.

Multicenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.

1.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

2.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

3.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

4.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

5.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

6.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

7.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

8.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers

9.

Hepatitis B virus infection in Belgium: preliminary results of the Belgian Association for the Study of the Liver (BASL) registry of HBsAg chronic carriers